The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PASG | -40.67% | -97.8% | -53.37% | -98% |
| S&P | +17.35% | +108.64% | +15.84% | +131% |
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.20M | 75.0% |
| Market Cap | $25.45M | -48.0% |
| Market Cap / Employee | $0.42M | 0.0% |
| Employees | 60 | 3.4% |
| Net Income | -$9.39M | 41.3% |
| EBITDA | -$10.13M | 37.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $57.63M | 132.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.14M | -5.8% |
| Short Term Debt | $3.59M | -2.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.58% | -7.6% |
| Return On Invested Capital | -61.90% | -31.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.33M | 51.8% |
| Operating Free Cash Flow | -$6.33M | 51.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.59 | 0.57 | 0.47 | 0.67 | 42.59% |
| Price to Tangible Book Value | 9.55 | 9.63 | 7.15 | 10.65 | 14.17% |
| Enterprise Value to EBITDA | 1.04 | 1.19 | 1.20 | 0.74 | -27.95% |
| Return on Equity | -69.1% | -75.1% | -83.7% | -88.3% | 38.90% |
| Total Debt | $25.82M | $25.48M | $25.12M | $24.73M | -5.43% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
